Enrico Martin

179 Emerging therapeutic targets 47. Kendall JJ, Chaney KE, Patel A V, Rizvi TA, Largaespada DA, Ratner N. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016;7(33):53191-53203. doi:10.18632/oncotarget.10668 48. Sweeney EE, Burga RA, Li C, Zhu Y, Fernandes R. Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Sci Rep. 2016;6:37035. doi:10.1038/srep37035 49. Semenova G, Stepanova DS, Dubyk C, et al. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. 2017;36(38):5421-5431. doi:10.1038/ onc.2017.143 50. Hirokawa Y, Nheu T, Grimm K, et al. Sichuan pepper extracts block the PAK1/ cyclin D1 pathway and the growth of NF1- deficient cancer xenograft in mice. Cancer Biol Ther. 2006;5(3):305-309. 51. Demestre M, Messerli SM, Celli N, et al. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice. Phytother Res. 2009;23(2):226-230. doi:10.1002/ptr.2594 52. Banerjee S, Byrd JN, Gianino SM, et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res. 2010;70(4):1356-1366. doi:10.1158/0008-5472.CAN-09-2178 53. Wu J, Patmore DM, Jousma E, et al. EGFR- STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 2014;33(2):173-180. doi:10.1038/onc.2012.579 54. Widemann BC, Meyer CF, Cote GM, et al. SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2016;34(15_suppl):11053. doi:10.1200/JCO.2016.34.15_suppl.11053 55. Hirokawa Y, Nakajima H, Hanemann CO, et al. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther. 2005;4(4):379- 381. 56. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71(1):185-196. doi:10.1158/0008-5472.CAN-10-2799 57. Patel A V, Eaves D, Jessen WJ, et al. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 2012;18(18):5020-5030. doi:10.1158/1078- 0432.CCR-12-1072 58. Mohan P, Castellsague J, Jiang J, et al. Genomic imbalance of HMMR/ RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. Oncotarget. 2013;4(1):80-93. doi:10.18632/oncotarget.793 59. Patel A, Liao CP, Chen Z, Liu C, Wang Y, Le L. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through bim induction. Cell Rep. 2014;6(1):81-92. doi:10.1016/j.celrep.2013.12.001 60. Lopez G, Bill KLJ, Bid HK, et al. HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS One. 2015;10(7):e0133302. doi:10.1371/journal. pone.0133302 61. Nair JS, Schwartz GK. Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression. Cell Cycle. 2015;14(19):3101-3111. doi:10.1 080/15384101.2015.1078033 62. Kivlin CM, Watson KL, Al Sannaa GA, et al. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther. 2016;17(2):129-138. doi:10.108 0/15384047.2015.1108486 7